Pharmaceutical sources revealed that 10 drugs accounted for about 65.84% of the sales of the French pharmaceutical company Sanofi in the Egyptian pharmaceutical market during the first half of this year, out of a total of more than 75 pharmaceutical preparations traded by the company in Egypt.
The sources said that the ten best-selling drugs of Sanofi in Egypt achieved sales worth EGP.3.1 billion out of its total sales during the period amounting to about EGP.4.707 billion, which represents 5.3% of the sales within the Egyptian pharmaceutical market.
The ten best-selling drugs of Sanofi in the Egyptian pharmaceutical market are represented by the following drugs
(Clexane) for treating blood clots with sales values of 625.4 million pounds and a market share of 13.2%
(Plavix) for preventing heart attacks with sales values EGP 447.3 million and a market share of 9.5%
(Telfast) for treating allergy symptoms with sales value of EGP 405.2 million and a market share of 8.6%
(Doliprane) analgesic and antipyretic with sales value of EGP 296.6 million and a market share of 6.3%
(Flagyl) an antibacterial drug with sales value of EGP 256.4 million and a market share of 5.4%
(Tavanic ) a broad-spectrum antibiotic with sales value of EGP 234 million and a market share of 4.99%
(Maxilase) an anti-inflammatory and anti-swelling drug with sales value of EGP 231.8 million and a market share of 4.93%
Insulin (LANTUS) for treating diabetes patients with sales value of EGP 231.8 million and a market share of 4.91%
(Amaryl) for treating diabetes patients with sales value of 231 million pounds and a market share of 4.8%
(Bronchicum) for treating cough and cold with sales value of 141.8 million pounds and a market share of 3%
